EL7.AI
StocksMedium•24 March 2026•
1 min read

FDA Grants Priority Review to Ionis' Alexander Disease Drug zilganersen

Key Facts

1The FDA granted Priority Review to Ionis Pharmaceuticals' New Drug Application (NDA) for zilganersen.
2The drug is intended to treat Alexander disease, a rare and serious genetic disorder.
3The FDA has set a PDUFA action date of September 22, 2026, for the approval decision.

Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its New Drug Application (NDA) for zilganersen. The investigational drug is designed to treat Alexander disease, a rare and potentially fatal genetic disorder that currently lacks approved therapies. This regulatory milestone follows positive results from Phase 3 clinical trials, which demonstrated the drug's efficacy in addressing significant unmet medical needs. The FDA has established a PDUFA action date of September 22, 2026, to finalize its decision regarding the drug's approval. A Priority Review designation accelerates the evaluation process, reflecting the urgency of providing treatments for serious conditions. Investors view this development as a positive step for Ionis, although the long-term timeline for commercialization remains a factor.